A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
NCT ID: NCT05532046
Last Updated: 2024-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
22 participants
INTERVENTIONAL
2022-09-20
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
BAY2413555 is a new compound which is under development for the treatment of heart failure. Heart failure is a serious disease in which the heart pumps less well. BAY2413555 is expected to protect the heart and improve cardiac function.
The main purpose of this study is to learn how safe BAY2413555 is compared to placebo in participants with chronic heart failure and implanted cardiac defibrillator, or cardiac resynchronization devices (ICD/CRT). A placebo is a treatment that looks like a medicine, but does not have any medicine in it. ICD/CRT are machines placed in the body that use an electric shock/impulse to reset the heart or get it beating correctly. To study the safety, the researchers will record all medical problems the participants may have during the study after starting the study treatment. Medical problems that happen after the participants have started their treatment are also known as "treatment emergent adverse events" (TEAEs). The TEAEs will be compared between participants who received BAY2413555 and those who received placebo.
The second purpose of this study is to learn whether BAY2413555 effects electrical signals inside the heart compared to placebo.
The study has two parts, A and B. Each part will last for two weeks. In part A, the participants will be assigned by chance to either take BAY2413555 as a tablet by mouth once per day or a placebo. Participants from part A who do not need to stop the study based on predefined criteria continue in part B. They will be assigned by chance to receive either the same dose of BAY2413555 as in part A or a higher dose. Participants who have taken placebo in part A will as well be assigned in part B.
Each participant will be in the study for approximately 90 days (including the screening period and follow-up period). In the study, participants will take study medication for 28 days. 8 visits to the study site and 1 telephone contact visit are planned. During the study, the study team will:
* do physical examinations
* check vital signs
* examine heart health using ECG
* check the participants' ICD/CRT information
* take exercise testing
* take blood and urine samples
* ask the participants questions about how they are feeling about their quality of life
* ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the study treatments or a study procedure. Participants will be closely monitored during the entire study duration and site personnel will take action to mitigate any negative effect, if any, as appropriate.
About 30 days after the participants take their last treatment, the study doctors and their team will check the participants' health.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
NCT01945606
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function
NCT05599997
Multiple Dose Study in Heart Failure of BAY 1067197
NCT02040233
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
NCT01067859
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
NCT01064037
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment arm 1
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
BAY2413555 Dose 1
BAY2413555 Dose 1
Treatment arm 2
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
BAY2413555 Dose 1
BAY2413555 Dose 1
BAY2413555 Dose 2
BAY2413555 Dose 2
Placebo
Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Placebo to BAY2413555
Placebo to BAY2413555
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BAY2413555 Dose 1
BAY2413555 Dose 1
BAY2413555 Dose 2
BAY2413555 Dose 2
Placebo to BAY2413555
Placebo to BAY2413555
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of heart failure lasting for at least 3 months, New York Heart Association (NYHA) functional class I-III prior to Visit 1
* Left ventricular ejection fraction (LVEF) ≤ 45% as documented by any imaging modality within the past 12 months prior to Visit 1
* Treatment with Guideline-Directed Medical Therapy Including with mandatory betablocker treatment with either Metoprolol, Carvedilol, Bisoprolol or Nebivolol on stable, highest individually tolerated dose for at least 2 weeks prior to Visit 1
* Implanted cardiac defibrillator (ICD) with pacemaker backup function OR cardiac resynchronization device (CRT)
* first implantation at least 3 months prior to Visit 1
Exclusion Criteria
* History of higher degree atrioventricular (AV) block (Mobitz type II or third-degree AV block) within 4 weeks prior to Visit 1
* Indication for or planned procedure:
* Planned cardiac surgery, carotid angioplasty or surgery, transcatheter aortic valve implantation (TAVI) or mitral valve clipping within 3 months starting from the Screening Visit
* Percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or implantation of a cardiac resynchronization therapy defibrillator device indicated at Screening or planned within 3 months starting from the Screening Visit
* Valvular Disease Repair indicated at Screening or planned within 3 months starting from the Screening Visit.
* Occurrence of any of the following within 4 weeks prior to Visit 1:
* Myocardial infarction
* Stroke or transient ischemic attack (TIA)
* coronary artery bypass graft (CABG)
* percutaneous coronary intervention (PCI)
* Carotid angioplasty
* Ablation therapy of atrial fibrillation or other rhythm abnormalities
* Heart rate (HR) \> 100 bpm at Screening Visit
* Restrictive, infiltrative or hypertrophic cardiomyopathy, constrictive pericarditis, acute myocarditis within 3 months prior to Visit 1
* Malignancy of the hematological system within 5 years prior to the Screening Visit
* Listed for heart transplantation and/or anticipated implantation of a ventricular assist device at the Screening Visit
* Hepatic insufficiency classified as Child-Pugh B or C at the Screening Visit
* Estimated (according to the investigator's judgement) inability to perform exercise testing
* Any of the following from the blood sample taken at the Screening Visit
* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2 (calculated according to the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation)
* Hemoglobin \< 11 g/dL
* White blood cell (WBC) \< 3000/mm\^3
* Thrombocytes \< 100 000/mm\^3
* Currently receiving or planned to receive dialysis or ultrafiltration
* Chronic obstructive pulmonary disease (COPD) Stage 3 or 4 (GOLD criteria), requiring treatment, or symptomatic asthma requiring current treatment
* Prior or concomitant therapy with cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or inducers.
Relevant substances need to be discontinued
* at least 2 weeks before randomization for CYP3A4 inducers
* at least 5 half-lives before randomization for CYP3A4 inhibitors Restarting of these therapies is possible 28 days after last intake of study intervention. This criterion also applies to other inhibitors of CYP3A4, e.g., grapefruit.
Prior and concomitant therapy with amiodarone is allowed.
* Concomitant treatment with acetylcholine esterase inhibitors within 4 weeks prior to Visit 1
* Use of other investigational drugs. Previous (within 4 weeks, or 5 half-lives of the investigational drug, whichever is longer, prior to Visit 1) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s)
* Life expectancy \< 6 months at the Screening Visit
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Accel Research Sites - Atlanta Clinical Research Center
Atlanta, Georgia, United States
White Oak Medical Center
Silver Spring, Maryland, United States
Capital Area Research, LLC
Camp Hill, Pennsylvania, United States
Capital Region | Gentofte Hospital - Cardiology Research
Hellerup, , Denmark
Odense Universitetshospital, Hjertemedicinsk Amb.
Odense C, , Denmark
Zealand University Hospital | Roskilde - Cardiology Department
Roskilde, , Denmark
Pratia | Klinische Forschung Dresden
Dresden, Saxony, Germany
Barzilai Ashkelon University Medical Center | Cardiology Department
Ashkelon, , Israel
Rambam Health Care Campus | Internal Medicine - Cardiology Department
Haifa, , Israel
Ziv Medical Center | Cardiology Department
Safed, , Israel
Humanitas Research Hospital | Cardio Center - Clinical, Interventional Cardiology and Coronary Care
Milan, Lombardy, Italy
Fondazione Toscana Gabriele Monasterio | Heart Hospital Gaetano Pasquinucci - Cardiology Department
Pisa, Tuscany, Italy
Hospital Alvaro Cunqueiro | Cardiology Department
Babio - Beade, Pontevedra, Spain
Hospital del Mar | Cardiology Department
Barcelona, , Spain
Hospital Universitari de Bellvitge | Bellvitge Biomedical Research Institute - Cardiology Department
Barcelona, , Spain
Junta de Andalucía | University Hospital Reina Sofia - Cardiology Department
Córdoba, , Spain
Hospital Universitario Virgen de la Victoria | Cardiology Department
Málaga, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find further information and, after study completion, the study results according to Bayer's transparency standards
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-005751-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
20623
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.